FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2460794815> ?p ?o ?g. }

• W2460794815 endingPage "40" @default.
• W2460794815 startingPage "34" @default.
• W2460794815 abstract "Neoadjuvant chemotherapy (NCT) is a standard of care for locally advanced and initially inoperable breast cancer. NCT can test chemotherapy efficacy and can be followed by breast-conserving surgery. Considering taxanes as one of the most effective agents, we analyzed the efficacy of a neoadjuvant schedule without anthracyclines and based only on taxanes and carboplatin, trying to avoid cardiotoxicity, which is the most serious side effect correlated with anthracyclines.We enrolled 61 patients with breast cancer, belonging to 4 subgroups, according to molecular phenotypes: 24 triple-negative/basal-like, 13 HER2-like, 20 luminal B, and 4 luminal A. All patients underwent weekly chemotherapy with carboplatin AUC2, paclitaxel 80 mg/m2, with trastuzumab (in case of HER2 positivity) 2 mg/kg, except for luminal A patients, who underwent only hormonal therapy. Among 61 patients, 26 (43%) received modified radical mastectomy and 35 (57%) received breast-conserving surgery.The patients obtaining pathologic complete response (pCR) were 20 (83%) of 24 triple-negative/basal-like, 10 (76%) of 13 HER2-like, 6 (30%) of 20 luminal B, and 3 (75%) of 4 luminal A. All the patients were evaluated for toxicity: no grade 4 was detected, 5 patients experienced grade 3 neuropathy, then reverted to G2 after chemotherapy discontinuation. At a minimum follow-up of 5 years, median overall survival was 48 months.Taxane/carboplatin-based/anthracycline-free NCT is the best treatment for inoperable breast cancer in terms of efficacy and toxicity, because this approach avoids cardiotoxicity and obtains an optimal rate (64%) of pCR, with an important impact on survival." @default.
• W2460794815 created "2016-07-22" @default.
• W2460794815 creator A5016077552 @default.
• W2460794815 creator A5036007209 @default.
• W2460794815 creator A5054277168 @default.
• W2460794815 creator A5058036252 @default.
• W2460794815 creator A5060477608 @default.
• W2460794815 creator A5062016837 @default.
• W2460794815 creator A5065836656 @default.
• W2460794815 creator A5079593513 @default.
• W2460794815 date "2017-02-01" @default.
• W2460794815 modified "2023-10-02" @default.
• W2460794815 title "Anthracycline-Free Neoadjuvant Chemotherapy Ensures Higher Rates of Pathologic Complete Response in Breast Cancer" @default.
• W2460794815 cites W1937345898 @default.
• W2460794815 cites W1956784352 @default.
• W2460794815 cites W1987326983 @default.
• W2460794815 cites W1996039468 @default.
• W2460794815 cites W2010714248 @default.
• W2460794815 cites W2011845956 @default.
• W2460794815 cites W2019607817 @default.
• W2460794815 cites W2024298772 @default.
• W2460794815 cites W2037013151 @default.
• W2460794815 cites W2050933203 @default.
• W2460794815 cites W2053662475 @default.
• W2460794815 cites W2072772580 @default.
• W2460794815 cites W2086064725 @default.
• W2460794815 cites W2098775844 @default.
• W2460794815 cites W2099840869 @default.
• W2460794815 cites W2102090417 @default.
• W2460794815 cites W2105219549 @default.
• W2460794815 cites W2117984780 @default.
• W2460794815 cites W2118605519 @default.
• W2460794815 cites W2132893003 @default.
• W2460794815 cites W2133540687 @default.
• W2460794815 cites W2133764807 @default.
• W2460794815 cites W2142486051 @default.
• W2460794815 cites W2146384083 @default.
• W2460794815 cites W2147415463 @default.
• W2460794815 cites W2148860061 @default.
• W2460794815 cites W2149908785 @default.
• W2460794815 cites W2157840751 @default.
• W2460794815 cites W2159710773 @default.
• W2460794815 cites W2165824128 @default.
• W2460794815 cites W2171431790 @default.
• W2460794815 cites W2176967157 @default.
• W2460794815 cites W2291500685 @default.
• W2460794815 cites W3014653200 @default.
• W2460794815 cites W806321452 @default.
• W2460794815 doi "https://doi.org/10.1016/j.clbc.2016.06.010" @default.
• W2460794815 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27435626" @default.
• W2460794815 hasPublicationYear "2017" @default.
• W2460794815 type Work @default.
• W2460794815 sameAs 2460794815 @default.
• W2460794815 citedByCount "5" @default.
• W2460794815 countsByYear W24607948152017 @default.
• W2460794815 countsByYear W24607948152021 @default.
• W2460794815 countsByYear W24607948152022 @default.
• W2460794815 crossrefType "journal-article" @default.
• W2460794815 hasAuthorship W2460794815A5016077552 @default.
• W2460794815 hasAuthorship W2460794815A5036007209 @default.
• W2460794815 hasAuthorship W2460794815A5054277168 @default.
• W2460794815 hasAuthorship W2460794815A5058036252 @default.
• W2460794815 hasAuthorship W2460794815A5060477608 @default.
• W2460794815 hasAuthorship W2460794815A5062016837 @default.
• W2460794815 hasAuthorship W2460794815A5065836656 @default.
• W2460794815 hasAuthorship W2460794815A5079593513 @default.
• W2460794815 hasConcept C121608353 @default.
• W2460794815 hasConcept C126322002 @default.
• W2460794815 hasConcept C143998085 @default.
• W2460794815 hasConcept C2776694085 @default.
• W2460794815 hasConcept C2776802502 @default.
• W2460794815 hasConcept C2777511904 @default.
• W2460794815 hasConcept C2778233292 @default.
• W2460794815 hasConcept C2778239845 @default.
• W2460794815 hasConcept C2778292576 @default.
• W2460794815 hasConcept C2779786085 @default.
• W2460794815 hasConcept C2780110267 @default.
• W2460794815 hasConcept C2781190966 @default.
• W2460794815 hasConcept C2781451048 @default.
• W2460794815 hasConcept C530470458 @default.
• W2460794815 hasConcept C71924100 @default.
• W2460794815 hasConceptScore W2460794815C121608353 @default.
• W2460794815 hasConceptScore W2460794815C126322002 @default.
• W2460794815 hasConceptScore W2460794815C143998085 @default.
• W2460794815 hasConceptScore W2460794815C2776694085 @default.
• W2460794815 hasConceptScore W2460794815C2776802502 @default.
• W2460794815 hasConceptScore W2460794815C2777511904 @default.
• W2460794815 hasConceptScore W2460794815C2778233292 @default.
• W2460794815 hasConceptScore W2460794815C2778239845 @default.
• W2460794815 hasConceptScore W2460794815C2778292576 @default.
• W2460794815 hasConceptScore W2460794815C2779786085 @default.
• W2460794815 hasConceptScore W2460794815C2780110267 @default.
• W2460794815 hasConceptScore W2460794815C2781190966 @default.
• W2460794815 hasConceptScore W2460794815C2781451048 @default.
• W2460794815 hasConceptScore W2460794815C530470458 @default.
• W2460794815 hasConceptScore W2460794815C71924100 @default.
• W2460794815 hasIssue "1" @default.
• W2460794815 hasLocation W24607948151 @default.

• next